Contact Us: 01282 426380
KM Financial Solutions | ‘Medicaid best price’ changes aimed at value-based gene therapy contracts -U.S. agency
75475
post-template-default,single,single-post,postid-75475,single-format-standard,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-child-theme-ver-1.0.0,qode-theme-ver-11.2,qode-theme-bridge,wpb-js-composer js-comp-ver-5.2.1,vc_responsive
 

‘Medicaid best price’ changes aimed at value-based gene therapy contracts -U.S. agency

16 Jun ‘Medicaid best price’ changes aimed at value-based gene therapy contracts -U.S. agency

Posted at 20:26h in News by
0 Likes
Proposed changes to requirements that
state-run Medicaid programs are given the best drug prices would
clear the way for commercial health insurers to enter into
“value-based” payment schemes, the U.S. Centers for Medicare &
Medicaid Services said on Wednesday.

No Comments

Sorry, the comment form is closed at this time.